主题
审稿人外联邮件模板（W3-W4 第一波）
版本: v0.8 (草稿) · 更新: 2026-04-28 版本史: v0.7（2026-04-28 删 career-stage 预设）· v0.6（2026-04-28 patient-facing reframe）· v0.5（2026-04-27 分层）· v0.4（2026-04-27 vision + research offer）· v0.3（2026-04-27 Managing Editor 身份）· v0.2（2026-04-26 relationship-first）· v0.1（2026-04-26 初稿） 上级: 审稿人 Playbook · 90 天路线图 W1-W4状态: 🟡 草稿待创始人审核 → 修订 → 发出
v0.8 关键调整（v0.7 → v0.8）
问题：v0.7 §3 Oscar 那封里专门写了一段 "I should also confess a slight bias: ... soft spot for anyone whose path crosses the Strand-and-Gower-Street axis." — 这是刻意攀校友关系的话术，读起来像销售。
修复：删掉单独的"confess bias"段，把 UCL/KCL 经历自然合并到自我介绍段，用一句温情但克制的表达（"the teachers I had there still shape how I read clinical writing today"），暗中给 Oscar 一个校友连接信号，但不显山不露水。
| 位置 | 旧（v0.7） | 新（v0.8） |
|---|---|---|
| §3 Oscar 单独段 | "I should also confess a slight bias: I'm a UCL alumnus and spent some time as an RA at KCL before moving back to China, so I have a soft spot for anyone whose path crosses the Strand-and-Gower-Street axis." | 删除整段 |
| §3 Oscar 自我介绍 | "I'm Shuangrui CHEN, the managing editor of WellChina..." | "I'm Shuangrui CHEN, the managing editor of WellChina... My own training was on the UK side — UCL, then a short stint as an RA at KCL before moving back — and the teachers I had there still shape how I read clinical writing today." |
§1 / §2 / §3B / §3C 的 UCL/KCL 提法保持不变 — 那几封 UK 经历是用来 contextualize "editorial vs clinical" 视角，本来就合并在自我介绍里，没有单独攀关系段。
v0.7 关键调整（v0.6 → v0.7）
问题：v0.6 在 §3B / §3C 里 implicitly 把对方定位成 "senior who watched research come out of an institution" 或 "junior still close to bench and chair, not yet in administration"。即使是恭维，预设对方的 career stage 或 role 都是不礼貌的——senior 看了会觉得"你说我远离 bench 了"，junior 看了会觉得"你说我没有行政地位"。
修复：4 处 surgical 替换——把 career-stage / role 的预设全部移除，改成把信息不对称放在自己身上（"I'd rather hear specifics than keep building on my own assumptions"）。
| 位置 | 旧（v0.6） | 新（v0.7） |
|---|---|---|
| §3B 末尾 | "from where you sit, with the research you've watched come out of [their institution]" | "from where you sit, it might look quite different — that's exactly why I'd value hearing your read" |
| §3C 开头 | "the next generation of Chinese stomatology researchers" | "Chinese stomatology researchers"（删 "next generation of"） |
| §3C 中段 | "I think researchers at your career stage often have the sharpest read on it" | "I'm mostly curious about something specific" |
| §3C 末段 | "the answers from people still close to both bench and chair are usually more specific than the answers from people who've moved further into administration" | "I'd rather hear specifics from someone close to the work than keep building on my own assumptions" |
v0.6 关键调整（v0.5 → v0.6）
| 维度 | v0.5 | v0.6 |
|---|---|---|
| 第一封"好奇问题"焦点 | 倾向研究方向 / 学术-信息生态 gap | 🔥 全部 reframe 成 patient-facing 问题 — 让第二封 §7 转向 reviewer 邀约 frictionless |
| §3C byline 暗示括号 | 保留 | 删除 — 不显得 sales-y |
| Tier S 第三位 | 待选 | Prof. Jiejun Shi（ZJU Ortho Director + 中国正畸学会常委）— ortho 维度补全 |
| Tier 1 第六位 junior | 待补 | Dr. Wenjie Zhou（Shanghai Ninth + Harvard ITI Scholar 2017-18 + Goethe Frankfurt 2024-25）— 上海九院 + 跨国研究背景 |
为什么 reframe 是关键
旧版本的"好奇问题"段（v0.5）问的是："how do you see the gap between Chinese stomatology research being produced and how little reaches the international patient information ecosystem"。
这是研究层面的话题。如果对方回复了，第二封 §7 要把话题拉回到"我们邀请你审一篇 dental tourism patient guide"——这是个 awkward pivot，对方可能感觉"我以为我们要谈学术合作，怎么变成审稿了？"
v0.6 的 reframe：第一封问题直接锚在 patient-facing materials 的品质——这正是 reviewer 工作内容。
| 问题层 | 旧（研究 layer） | 新（patient-facing layer） |
|---|---|---|
| 抽象层 | "research vs information ecosystem gap" | "what should a foreign patient be able to read before they fly here" |
| 转向 §7 | 突兀（research → reviewer） | 自然（"your point is exactly what a reviewer would flag before we publish"） |
| 对方回复门槛 | 要求 systemic 反思 | 给一个具体可观察的洞察（"我看到的患者最常误解 X"） |
⚠️ Conflict of Interest 校准（沿用）
- 🟢 First choice：研究方向 PI / 学术教授 / 公立大三甲编内年轻医生 / postdoc（无临床抢患者压力）
- 🟡 Backup：跨太平洋临床医生（中等 conflict，合同必须限定不审涉及自身雇主的内容）
- 🔴 Lower priority：私立诊所 / 国际部临床医生（高 conflict，schema sameAs 多样性候选 only）
设计原则（v0.3-v0.6 累积）
| 原则 | 内容 |
|---|---|
| 语言 | 全部英文 |
| 第一封目标 | 建立联系，争取得到回复，不约视频 |
| 信息密度 | 不提钱、不提样审、不提合同（留到 §7 第二封） |
| 身份梯度 | 第一封 Managing Editor → 第二封 Founder & Managing Editor |
| 创始人英文名 | Shuangrui CHEN |
| Hook | 对方独有经历的 patient-facing 好奇问题 + UCL/KCL 轻量套近乎 + 平台 vision + 研究协作 offer |
| Ask | "如果哪天有兴趣交流想法，欢迎回信" |
| 字数 | 200-280 字 |
§0 共享段落
Vision 段（每封都用，2-3 句）
Our hope is that, five years from now, when someone in Tokyo, Seoul,
Jakarta, Mumbai, or São Paulo searches for dental care or specialty
treatment in China, the first reliable source they reach is a
peer-reviewed, multilingual information layer — not vendor marketing
or scattered expat-forum threads. That's the gap we're trying to
close, slowly and carefully.Research-collaboration offer 段（仅研究型 PI / postdoc / Asst Prof 邮件用）
We're equally interested in being useful to research that intersects
with cross-border patient information. We're early — at the moment we
mostly have multilingual editorial workflows and a small set of
search analytics — but as we accumulate anonymized search-trend data
across our eight language audiences, query patterns surfacing gaps
in current clinical-communication literature, and de-identified
case-pattern data collected under proper consent, we'd hope to be
able to share what's relevant with collaborators who can put it to
better use than we can ourselves. If any of that touches a research
direction your team is currently working on, we'd be glad to keep
it in mind.§1 Email — Sandy TANG / 唐思青（SH UFH · ABO Diplomate · 🟡 backup）
Conflict note：合同需限定不审涉及 SH UFH / 同业雇主的内容。 Subject: A note on cross-Pacific orthodontic communication — from one editor across the field
Dear Dr. Tang,
I came across your profile while researching how clinicians who
trained across both the West China and U.S. orthodontic systems
think about patient communication. Your trajectory — West China
Stomatology → U Maryland → Vanderbilt residency → three years at
Lovett Dental in Houston → back to Shanghai United Family — is one
of the more deliberate cross-Pacific paths I've seen, and the ABO
Diplomate on top is genuinely rare in mainland China.
I'm Shuangrui CHEN, the managing editor of WellChina (wellchina.top),
an information platform that helps international patients navigate
medical care in China. My own background is in the UK academic system
(UCL alumnus, briefly an RA at KCL), so the problem of translating
clinical practice across very different training cultures is one
I find genuinely fascinating.
[VISION PARAGRAPH FROM §0]
I'm not writing with any specific ask today — I'm mostly curious
about something I imagine you see often: when you walk a foreign
patient through a treatment plan that was originally framed in
West-China-system clinical language, what's the part of that
translation you wish was already done well in writing — before
they walked into your chair? My instinct is that the gap there
is much wider than how it's usually described, but I'd value a
clinician's read.
If you ever feel like trading thoughts on it — by email, no rush,
no calendar — I'd genuinely value hearing your perspective.
Either way, thank you for the work you do for international
families in Shanghai.
Best,
Shuangrui CHEN
Managing Editor, WellChina
https://wellchina.top§2 Email — Sam DING, DDS, PhD（Jiahui · Implant 2000+ · 🟡 backup）
Conflict note：合同限定不审 Jiahui 内容。 Subject: A question on cross-system implant choice — from a fellow editor across the field
Dear Dr. Ding,
I came across your Jiahui profile while reading about how senior
implant clinicians in China think about choosing between the major
implant systems (Nobel, Straumann, 3I, Osstem, Dentium). It's
unusual to find someone who has worked across all five at scale —
your 2,000+ case experience with that range is the kind of
cross-system view that international patients almost never get
exposed to before they decide where to fly for treatment.
I'm Shuangrui CHEN, the managing editor of WellChina (wellchina.top),
an information platform helping foreign patients understand medical
care in China. My own background is in the UK academic system (UCL
alumnus, briefly an RA at KCL), which gives me a certain angle on
European prosthodontics literature — but the China implant
landscape is a different world, and the cross-system perspective
is much harder to find in writing than I assumed.
[VISION PARAGRAPH FROM §0]
I'm not writing with a specific proposal today — I'm mostly curious
about a moment you must see frequently: when an international
patient sits in your chair after having read half a dozen
conflicting English articles about implant systems, what's the
one thing they most often have wrong — that should have been
corrected in the writing before they got there? That mismatch is
exactly the gap I'm trying to learn how to think about.
If you ever feel like sharing a few thoughts by email, no rush
and no calendar required, I'd genuinely value the perspective.
Either way, thank you for the work you do for the patients who
walk into Jiahui every week.
Best,
Shuangrui CHEN
Managing Editor, WellChina
https://wellchina.top§3 Email — Dr. Oscar Sum（Aidencare · KCL/NHS · 🔴 lower priority · 校友 hook 试探）
Conflict note：高 conflict，Phase B 试一封看回应。 Subject: From a UCL alumnus & former KCL RA — a question on AI in dental practice
Dear Dr. Sum,
I came across your Aidencare profile and had to read it twice — KCL
DDS + NHS Brighton GDS + a Master's in Dental AI + a multilingual
practice in Shanghai is a combination I genuinely haven't seen
elsewhere. Most of the public conversation about AI in dentistry
right now lives in vendor marketing; the perspective of someone who
has actually trained in both clinical practice and the AI side
feels much harder to find.
I'm Shuangrui CHEN, the managing editor of WellChina
(wellchina.top), an information platform helping foreign patients
navigate medical care in China. My own training was on the UK
side — UCL, then a short stint as an RA at KCL before moving
back — and the teachers I had there still shape how I read
clinical writing today.
[VISION PARAGRAPH FROM §0]
I'm not writing with a specific proposal today — I'm mostly curious
how you think the next few years of AI tooling will (or won't)
change what foreign patients should be able to read about a
Shanghai dental clinic before they decide to fly here. The vendor
narrative says AI changes everything; my instinct is that it
changes much less than the marketing claims, but in specific
patient-facing places it matters a lot. I'd value a clinician's read.
If you ever feel like sharing a few thoughts on that by email,
no rush and no calendar required, I'd genuinely enjoy the exchange.
Either way, thank you for the cross-cultural work Aidencare does
in Shanghai.
Best,
Shuangrui CHEN
Managing Editor, WellChina
https://wellchina.top§3B Email — 大佬级 PI 通用模板（🟢 Tier S · 3 封长尾试探）
适用对象：Zhou Yongsheng / Bei Wu / Jiejun Shi。
Subject: An editorial inquiry from WellChina — and a question on [research focus]
Dear Professor [LastName],
I've spent some time with your work on [SPECIFIC RESEARCH AREA]
while trying to understand how China's leading research-side
dentistry is shaping the clinical practice that international
patients will encounter when they fly here.
[OPTIONAL respectful one-liner — keep it short and factual.
A general nod to institutional standing or distinguished-scientist
status is the safer register than singling out one paper that
may be peripheral to current focus.]
I'm Shuangrui CHEN, the managing editor of WellChina
(wellchina.top), an information platform helping foreign patients
navigate medical care in China. We publish in eight languages.
My own background is in the UK academic system (UCL alumnus,
briefly an RA at KCL), so I'm coming at this from an editorial
angle rather than a clinical one.
[VISION PARAGRAPH FROM §0]
I'm not writing with a specific proposal today — I'm reaching out
because I'd be curious what you think a foreign patient should
ideally be able to read, in their own language, about [research
area / specialty] before they make a treatment decision in China —
and how far that is from what they actually find today. From an
editorial seat the gap looks wide; from where you sit, it might
look quite different — and that's exactly why I'd value hearing
your read.
[RESEARCH-COLLABORATION OFFER FROM §0]
If any of this resonates and you'd like to trade thoughts by email,
no rush and no calendar required, I'd genuinely value hearing your
perspective.
With respect,
Shuangrui CHEN
Managing Editor, WellChina
https://wellchina.top§3B 适配示例 — Prof. Zhou Yongsheng（PKU SS President）
| Placeholder | 填什么 |
|---|---|
| Subject | An editorial inquiry from WellChina — and a question on prosthodontic rehabilitation across patient populations |
| Specific research area | "stem-cell-based bone regeneration and digital prosthodontic rehabilitation" |
| Respectful one-liner | "Your stewardship of the National Clinical Research Center for Oral Diseases makes the question I'm sitting with feel especially worth asking the right person." |
| Their institution | "PKU School of Stomatology" |
| 收件人 | kqzhouysh@hsc.pku.edu.cn（公开） |
§3B 适配示例 — Prof. Bei Wu（NYU Shanghai Provost）
| Placeholder | 填什么 |
|---|---|
| Subject | An editorial inquiry from WellChina — and a question on geriatric oral health across Chinese populations |
| Specific research area | "geriatric oral health and the broader public-health framing of dental care" |
| Respectful one-liner | "Your decades of work bridging Chinese and Chinese-American oral-health epidemiology has been a quiet anchor for how we've tried to think about cross-population framing in our editorial workflow." |
| Their institution | "NYU and NYU Shanghai" |
| 收件人 | NYU Shanghai 公开邮箱 |
§3B 适配示例 — Prof. Jiejun Shi（ZJU Stomatology Ortho Director）
| Placeholder | 填什么 |
|---|---|
| Subject | An editorial inquiry from WellChina — and a question on orthodontic communication across patient populations |
| Specific research area | "craniofacial deformity growth, occlusion, and TMJ-related orthodontic care" |
| Respectful one-liner | "Your standing committee role with the Chinese Orthodontic Society has shaped how the field's senior voices get framed for younger clinicians, and I imagine that perspective extends to how the field reaches patients too." |
| Their institution | "Zhejiang University Stomatology" |
| 收件人 | ZJU Stomatology 公开 |
§3C Email — 年轻研究医生通用模板（🟢 Tier 1 · 主战场 6 封）
适用对象：副主任医师 / 主治医师 / 博士后 / Assistant Professor / 博士在读高年级。
关键差异（vs §3B 大佬版）：
- Hook：从"institutional standing" → "recent paper / early-career trajectory"
- 末尾 byline 暗示括号 已删除（v0.6） — 不让对方感到被推销
Subject: An editorial note from WellChina — and a question on [their recent research focus]
Dear Dr. [LastName],
I came across your recent work on [SPECIFIC RECENT PAPER OR
RESEARCH DIRECTION — preferably a 2023-2025 paper they were first
or co-corresponding author on] while trying to understand how
Chinese stomatology researchers are reframing [implantology /
orthodontics / periodontics / etc.] for an increasingly
international patient population.
I'm Shuangrui CHEN, the managing editor of WellChina
(wellchina.top), an information platform helping foreign patients
navigate medical care in China. We publish in eight languages.
My own background is in the UK academic system (UCL alumnus,
briefly an RA at KCL), and I'm coming at this from an editorial
angle rather than a clinical one.
[VISION PARAGRAPH FROM §0]
I'm not writing with a specific proposal today — I'm mostly
curious about something specific: when a foreign patient is about
to make a decision about [their specialty area] in China, what's
the one thing they most need to read in plain language, in their
own tongue, that they currently can't find anywhere in English?
That gap has been bothering me, and I'd rather hear specifics
from someone close to the work than keep building on my own
assumptions.
[RESEARCH-COLLABORATION OFFER FROM §0]
If any of this resonates and you'd like to trade thoughts by
email, no rush and no calendar required, I'd genuinely value
hearing your perspective.
With respect,
Shuangrui CHEN
Managing Editor, WellChina
https://wellchina.top§3C 适配示例
| 候选 | Specific paper / direction 填什么 | Specialty area | 收件人 |
|---|---|---|---|
| 冯剑颖 / Feng Jianying (Hangzhou Dental, 主治) | "your SCI publications on orthodontic practice from a public-hospital attending perspective" | "orthodontic care" | Hangzhou Dental 国际部 / LinkedIn |
| Dr. Jianxia HOU (PKU SS, perio) | "your work on periodontology — the 67-paper trajectory on ResearchGate is hard to miss" | "periodontal care and gum-disease prevention" | PKU SS 公开 / ResearchGate DM |
| Dr. Wenjie Zhou (Shanghai Ninth, Assoc Prof, Harvard ITI Scholar) | "your work on regenerative implant dentistry, including your scholar years at Harvard School of Dental Medicine and Goethe University Frankfurt Carolinum" | "implant dentistry and regenerative work" | Shanghai Ninth 公开 / ResearchGate DM |
| Xiong XIN (West China Stomatology, Asst Prof) | "your recent work as an early-career assistant professor at one of China's foundational stomatology schools" | "[待查具体方向]" | 华西公开 / ResearchGate DM |
| Yanjie Wang (Xiangya, Resident) | "your March 2025 first-author paper on dental implants — an unusual level of independent publication for someone still in residency" | "implant dentistry" | Xiangya 公开 |
| Lingling Zhang (Xiangya, Asst Prof) | "your co-authored work with [Yanjie Wang] on implant outcomes" | "implant dentistry" | Xiangya 公开 |
§4 Email — 学术机构国际部（v0.5/v0.6 暂不发）
模板保留，等 W4-W5 看年轻研究医生回复率再决定是否启动作为 Plan A fallback。完整模板见 v0.4 doc 历史。
§5 跟进邮件 — 7 天无回复时使用
Subject: Re: [original subject]
Dear Dr. [LastName],
Just a light nudge in case my earlier note got buried — no
expectation of a response, and absolutely no offense taken if
this isn't a good moment for you.
If at any point in the future you'd be open to trading thoughts
on [topic from §1-§3C], I'm easy to reach at this address.
Wishing you a good week,
Shuangrui CHEN
WellChina§6 跟进邮件 #2 — 再 7 天无回复时使用（最后一封）
Subject: Re: [original subject]
Dear Dr. [LastName],
Last note from me on this thread — I don't want to clutter your
inbox further. I'll close the loop here.
If anything ever changes and you'd like to be in touch, you can
reach me at this address any time.
With respect,
Shuangrui CHEN
WellChina§7 第二封模板（对方回复后才使用）
对方回复 = "第二封的入场券"。这一封进入实质合作内容，才把 founder 身份补出来。
v0.6 reframe 后的优势：第一封问的是 patient-facing materials gap，对方回复必然包含他们看到的具体 mismatch（"患者经常误解 X" / "应该读 Y 但读不到"）。这一封直接说"那正是 reviewer 工作"。
Subject: Re: [original thread]
Dr. [LastName],
Thank you — your point about [echo something specific they said,
e.g. "patients arriving with the wrong mental model of immediate-load
implants"] is exactly the kind of thing a reviewer in our network
would flag before we publish. I'd love to keep the conversation
going.
A bit more context on what I'm building: WellChina is something I
founded as well as edit, and we are putting together a small
medical-review and editorial-collaboration network — clinicians
and researchers who help us pressure-test the factual accuracy
of the English-language content we publish for international
patients, and who occasionally co-shape the editorial direction
on questions where their expertise is decisive.
It's a freelance, byline-credited engagement (modeled on the
Healthline / WebMD reviewer-byline pattern, with credentials and
a public-profile link shown on each reviewed article). For
research-side collaborators, the byline is listed as "Editorial
Advisor" rather than "Reviewer", and we're additionally open to
formal research collaboration on shared questions.
I'd be glad to share more — engagement model, compensation, scope,
the contract framework, examples of editorial advisor vs reviewer
roles — if you'd like to look. Happy to send a one-pager you can
read on your own time, or set up a 15-minute call if that's
easier.
Either way, no pressure, and thank you for the exchange so far.
Best,
Shuangrui CHEN
Founder & Managing Editor, WellChina
https://wellchina.top§8 候选人池 v0.6（13 位 — Phase A 实发 9 位）
🟢 Tier S · 大佬级（3 封长尾试探）
| # | 候选 | 机构 | 角色 / 资质 | 邮件版本 | 渠道 |
|---|---|---|---|---|---|
| 1 | Prof. Zhou Yongsheng / 周永胜 | PKU School of Stomatology | President + Prosthodontics Director + 国家口腔疾病临研中心副主任 + ITI Fellow | §3B (Zhou 适配) | kqzhouysh@hsc.pku.edu.cn ✅ |
| 2 | Prof. Bei Wu | NYU Shanghai + NYU Meyers | Provost + Dean's Professor + Vice Dean for Research + 2017 IADR Distinguished Scientist + 900+ publications | §3B (Wu 适配) | NYU Shanghai 公开 |
| 3 | Prof. Jiejun Shi | Zhejiang University Stomatology | Director of Orthodontic Department + 中国正畸学会常委 + 10+ SCI papers | §3B (Shi 适配) | ZJU SS 公开 |
🟢 Tier 1 · 年轻研究医生（主战场，发 6 封）
| # | 候选 | 机构 | 角色 / 资质 | 邮件版本 | 渠道 |
|---|---|---|---|---|---|
| 4 | 冯剑颖 / Feng Jianying | Hangzhou Dental Hospital Qingchun branch | 主治医师 + DDS ZJU + 中华口腔正畸专委会 + 20+ papers (3 SCI) + 国家发明专利 | §3C 适配 | Hangzhou Dental 国际部 |
| 5 | Dr. Jianxia HOU | PKU School of Stomatology | Periodontology researcher + ResearchGate active（67 papers, 872 citations） | §3C 适配 | PKU SS 公开 / ResearchGate DM |
| 6 | Dr. Wenjie Zhou | Shanghai Ninth People's Hospital + 上交医 | Associate Professor + DDS/MDS/PhD + Harvard School of Dental Medicine ITI Scholar 2017-18 + Goethe Frankfurt Research Scholar 2024-25 | §3C 适配 | Shanghai Ninth 公开 / ResearchGate DM |
| 7 | Xiong XIN | Sichuan U / 华西口腔 | Assistant Professor + DDS + ResearchGate active | §3C 适配 | 华西公开 / ResearchGate DM |
| 8 | Yanjie Wang | Xiangya Stomatology / 中南大学 | Resident + March 2025 PubMed first-author publication on dental implants | §3C 适配 | Xiangya 公开 |
| 9 | Lingling Zhang | Xiangya Stomatology / 中南大学 | Assistant Professor + 同 #8 同 paper co-author | §3C 适配 | Xiangya 公开 |
🟡 Tier 2 · 跨太平洋临床医生（合同限定 backup）
| # | 候选 | 机构 | Conflict 处理 | 邮件版本 |
|---|---|---|---|---|
| 10 | Sandy TANG / 唐思青 | SH UFH | 合同限定不审 SH UFH 内容 | §1 |
| 11 | Wenlu JIANG | SH UFH | 同上 | §1 改名版 |
| 12 | Sam DING | Jiahui | 合同限定不审 Jiahui 内容 | §2 |
🔴 Tier 3 · 校友 hook 试探（保留 1 封）
| # | 候选 | 机构 | 用途 | 邮件版本 |
|---|---|---|---|---|
| 13 | Dr. Oscar Sum | Aidencare Shanghai | 校友连接试探 + schema sameAs 多样性候选 | §3 |
§9 第一波发送策略（v0.6 沿用 v0.5）
Phase A · W3 第一周发 9 封（分 3 天 × 3 封）
重心：6 位年轻研究医生 + 3 位大佬
- Day 1：#1 Zhou Yongsheng / #4 冯剑颖 / #5 Jianxia HOU
- Day 2：#2 Bei Wu / #6 Wenjie Zhou / #7 Xiong XIN
- Day 3：#3 Jiejun Shi / #8 Yanjie Wang / #9 Lingling Zhang
Phase B · W4 视 Phase A 结果决定
- 若 Phase A 回复 ≥ 3 → Phase B 不发临床；进入第二封 §7 阶段
- 若 Phase A 回复 1-2 → Phase B 补 Sandy + Sam（§1 §2 临床向 backup）
- 若 Phase A 回复 0 → 重新评估 spam 命中率 + email rendering，不要立即继续发
Phase C · W5+ 校友 hook 试探（独立周期）
- Oscar Sum（§3）— 当作 schema sameAs 多样性候选，独立周期发，与主 pipeline 解耦
回复率成功标准
- 建立联系率：≥ 3/9 收到任何形式回复 → hook 设计成功
- 进入第二封率：≥ 1/9 进入 §7 实质对话 → 进入 W4 Paid Sample Review 阶段
- 大佬 0 回复属正常，不当指标
§10 v0.6 关闭的开放问题
✅ 已拍板：
- Vision 段城市清单 — 5 城市保留
- Research offer 措辞 — 弱化为"in the future as we accumulate"
- Bei Wu hook — 改为对她整体学术地位的尊重式致意
- Jennifer Xu — 删除
- Oscar — 保留作 🔴 Phase C 试探
- 学术机构 — 暂不发，模板保留
- Tier S 第三位 — Jiejun Shi
- Tier 1 第六位 junior — Wenjie Zhou
- §3C byline 暗示括号 — 删除
- §3B / §3C / §1 / §2 / §3 好奇问题 — 全部 reframe 为 patient-facing
🟡 Phase A 启动前需要你最后 check 的 1 件事：
是否同意以现在的版本进入 Phase A 发送？
- 如果 OK → 我可以 commit + push 这版到 docs，然后你按 §9 节奏分 3 天发出去
- 如果还有任何 hook / 措辞修订 → 告诉我，我出 v0.7
相关文档
- 审稿人 Playbook §5 通用外联脚本 — 老版（v0.6 是 patient-facing reframe + 分层 + research offer 多轴重写）
- 审稿人 Playbook §7 入职流程 — 第二封后续阶段
- 内容稳定化 Playbook §5.2 Paid Sample Review — 第三阶段
- ToS 与合同 §5 Reviewer Agreement — 合同模板（v0.6 触发 update 需求：加 Editorial Advisor vs Reviewer 双角色 + 临床候选 conflict 限定条款）
- 90 天路线图 W3-W4 Gate — 整体节奏